Similar articles

• Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome.

  Vassiliades TA Jr, Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, Cates CU. Vassiliades TA Jr, et al. J Thorac Cardiovasc Surg. 2006 May;131(5):956-62. doi: 10.1016/j.jtcvs.2005.10.058. Epub 2006 Apr 27. J Thorac Cardiovasc Surg. 2006. PMID: 16678575
• Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.

  Ong AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW. Ong AT, et al. J Am Coll Cardiol. 2006 Apr 4;47(7):1356-60. doi: 10.1016/j.jacc.2005.05.102. Epub 2006 Mar 20. J Am Coll Cardiol. 2006. PMID: 16580521
• Drug-eluting stents are safe and effective: right or wrong?

  Sigwart U. Sigwart U. J Am Coll Cardiol. 2006 Apr 4;47(7):1361-2. doi: 10.1016/j.jacc.2006.02.001. Epub 2006 Mar 20. J Am Coll Cardiol. 2006. PMID: 16580522 No abstract available.
• A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.

  Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Jüni P, Pfisterer ME, Meier B, Kastrati A. Schömig A, et al. J Am Coll Cardiol. 2007 Oct 2;50(14):1373-80. doi: 10.1016/j.jacc.2007.06.047. Epub 2007 Aug 21. J Am Coll Cardiol. 2007. PMID: 17903638 Review.
• Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis.

  Nordmann AJ, Briel M, Bucher HC. Nordmann AJ, et al. Eur Heart J. 2006 Dec;27(23):2784-814. doi: 10.1093/eurheartj/ehl282. Epub 2006 Oct 4. Eur Heart J. 2006. PMID: 17020889 Review.